XNAS
VIR
Market cap760mUSD
Jul 14, Last price
5.50USD
1D
-2.65%
1Q
-2.14%
IPO
-60.12%
Name
Vir Biotechnology Inc
Chart & Performance
Profile
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
Income | ||||||||
Revenues | 74,205 -13.90% | 86,180 -94.55% | 1,580,472 45.39% | |||||
Cost of revenue | 507,344 | 592,436 | 620,967 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (433,139) | (506,256) | 959,505 | |||||
NOPBT Margin | 60.71% | |||||||
Operating Taxes | (1,145) | (13,077) | 238,443 | |||||
Tax Rate | 24.85% | |||||||
NOPAT | (431,994) | (493,179) | 721,062 | |||||
Net income | (521,960) -15.14% | (615,061) -219.24% | 515,837 -2.41% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 7,767 | 39,440 | ||||||
BB yield | -0.58% | -1.16% | ||||||
Debt | ||||||||
Debt current | 12,867 | 4,137 | ||||||
Long-term debt | 180,278 | 223,346 | 247,674 | |||||
Deferred revenue | 1,526 | 53,207 | ||||||
Other long-term liabilities | 38,627 | 40,218 | 32,799 | |||||
Net debt | (1,000,120) | (1,391,471) | (2,174,156) | |||||
Cash flow | ||||||||
Cash from operating activities | (446,352) | (778,785) | 1,663,253 | |||||
CAPEX | (7,301) | (21,573) | (68,028) | |||||
Cash from investing activities | 499,367 | 164,629 | (1,193,461) | |||||
Cash from financing activities | 4,388 | 7,480 | 34,761 | |||||
FCF | (387,657) | (472,213) | 1,180,311 | |||||
Balance | ||||||||
Cash | 990,383 | 1,522,409 | 2,402,040 | |||||
Long term investments | 190,015 | 105,275 | 23,927 | |||||
Excess cash | 1,176,688 | 1,623,375 | 2,346,943 | |||||
Stockholders' equity | (761,487) | (238,626) | 368,128 | |||||
Invested Capital | 2,040,638 | 1,995,146 | 1,908,587 | |||||
ROIC | 39.61% | |||||||
ROCE | 42.08% | |||||||
EV | ||||||||
Common stock shares outstanding | 136,247 | 134,131 | 134,811 | |||||
Price | 7.34 -27.04% | 10.06 -60.25% | 25.31 -39.55% | |||||
Market cap | 1,000,052 -25.89% | 1,349,357 -60.45% | 3,412,064 -38.93% | |||||
EV | (68) | (42,114) | 1,237,908 | |||||
EBITDA | (413,183) | (486,805) | 966,288 | |||||
EV/EBITDA | 0.00 | 0.09 | 1.28 | |||||
Interest | 183,145 | |||||||
Interest/NOPBT | 19.09% |